Key Highlights
- TFX is trading down 0.77% at $130.15 on October 21, with a market capitalization of about $5.51 billion.
- The company has not yet announced a third-quarter date; the second-quarter report came on August 6.
- Full-year adjusted EPS guidance was raised on August 6 to $6.90 to $7.20 from $6.25 to $6.55.
- Second-quarter adjusted EPS was $1.76, up 1.7%, on revenue of $570.3 million.
- Trailing EPS is a loss of $23.29, the P/E is blank and the dividend yield is 1.04%.
Is a Distorted Earnings Picture Hiding What Matters for Teleflex Ahead of Its Next Report?
Teleflex (NYSE:TFX) is trading down 0.77% at $130.15 on October 21, and no company announcement was identified for the session. The company has not yet announced the date of its third-quarter report. The second-quarter report came on August 6 before the open, so this is an early look.
What investors may be missing is that the trailing numbers are not a clean guide. Trailing EPS is a loss of $23.29, trailing EPS growth is negative 648.31% and the P/E is blank, all affected by large one-time items in the second half of 2025. The latest call is the better frame.
Teleflex makes medical devices in vascular access, interventional and surgical care. Market capitalization is about $5.51 billion.
What Did the Second-Quarter Call Set Up After the OEM Sale?
Second-quarter revenue from continuing operations was $570.3 million, up 28.9% as reported and 4.7% on a pro forma constant-currency basis. Adjusted EPS was $1.76, up 1.7%, with an adjusted operating margin of 19.6%. Vascular grew 8% to $246.3 million, surgical grew 9.2% to $112.1 million, and interventional fell 1% to $211.9 million as the integration of an acquired vascular intervention business weighed on results.
Management cut its 2026 pro forma constant-currency growth outlook to 3.5% to 4.5% from 4.5% to 5.5%, and raised adjusted EPS to $6.90 to $7.20 from $6.25 to $6.55. The adjusted operating margin is still about 19%, net interest expense is now about $85 million and the adjusted tax rate about 12.25%.
The OEM business sold for about $1.5 billion, roughly $1.25 billion after tax, and proceeds repaid a $700 million term loan. The plan is to cut debt by $800 million and return $1 billion through buybacks. The company bought about $250 million of stock in the second quarter and started a further $250 million accelerated repurchase on August 7.
What Would a Good or Bad Quarter Look Like for Teleflex?
Positive signals would be organic constant-currency growth inside or above the 3.5% to 4.5% range, interventional returning to growth as the order-to-cash and distributor changes settle, a steady adjusted margin near 19% and another increase to the EPS outlook.
Negative signals would be growth below the range, margin pressure after the divestiture or an outlook that is only held. Management expects vascular and surgical to grow more moderately in the second half, citing distributor inventory and tougher comparisons in instruments, and said full integration now runs through the second half of 2026, later than the mid-year target.
What Else Could Shape the Reaction?
The remaining $500 million of buybacks is expected to rely largely on the pending sale of the acute care and interventional urology business, targeted to close in the fourth quarter and subject to regulatory approval, with a second request from the FTC issued in March. Any update on timing will draw attention.
The dividend yield is 1.04% and the consensus analyst rating is Buy. Investors will check whether growth and EPS are comparable year over year before reading the reaction as good or bad.





_11_20_2026_12_38_15_908731.jpg)
Please wait processing your request...